Back to top

Image: Bigstock

Integra LifeSciences Expands Cadence System Commercially

Read MoreHide Full Article

Integra LifeSciences Holdings Corporation (IART - Free Report) , a global medical technology company, recently announced full commercial expansion of its Cadence Total Ankle System. The company developed the new ankle prosthesis in collaboration with renowned foot and ankle surgeons.

The Cadence Total Ankle System was earlier available in limited markets. It is now fully available in the U.S., Canada and selected European countries. 

Users have been increasingly relying on the system, courtesy of the improvement in implant and instrument design along with a streamlined surgical technique. The prosthesis includes several features to reduce potential clinical complications and address common issues with ankle arthroplasty procedure.
 
For the last three months, Integra has been trading below the Zacks categorized Medical - Biomedical and Genetics industry. The stock has lost 0.7%, comparing unfavorably with the industry’s 6.4% gain. We expect the complete roll out of its Cadence Total Ankle System to boost the share price.


 

Notably, Cadence total ankle procedures have been successfully performed in seven countries, since its initial clinical use more than a year ago. The streamlined and reliable operative instruments and techniques of the procedure offer significant advantages over other ankle systems existing in the present market.

The company also plans to initiate several global post-market clinical studies with the Cadence system to further support product efficacy.

Meanwhile, Integra completed corrective measures required to close an FDA recall. The recall was related to the clarification of the occurrence of a small percentage of intra-operative posterior tibial fractures due to technique error of the system. The recall however did not require withdrawal of the product. Since the implementation of the clarified surgical technique, no subsequent posterior tibial fractures have occurred in more than 100 procedures.

As per a MarketsandMarkets report, the global foot and ankle devices market is expected to reach a worth of $5.41 billion by 2020 at a CAGR of 7.2%. Given the growing aging population and pressing demand for arthritis treatment, Integra is expected to cash in on these opportunities.

Zacks Rank & Key Picks

Integra LifeSciences currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are Inogen, Inc. (INGN - Free Report) , Orasure Technologies, Inc. (OSUR - Free Report) and ZELTIQ Aesthetics, Inc. . While Inogen sports a Zacks Rank #1 (Strong Buy), Orasure and ZELTIQ Aesthetics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Inogen gained 83.2% in the last one year in comparison to the S&P 500’s gain of 14.3%. The company has a stellar four-quarter positive average earnings surprise of over 49.08%.

Orasure surged 76.8% in the last one year in comparison to the S&P 500. It has a four-quarter positive average earnings surprise of 123.5%.

ZELTIQ Aesthetics gained over 100% in the past one year, better than the S&P 500 mark. It also has a trailing positive average earnings surprise of 12.03%.

More Stock News: 8 Companies Verge on Apple-Like Run

Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.

A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>

Published in